References
- Ramsey SD, Lyman GH, Bangs R. Addressing skyrocketing cancer drug prices comes with tradeoffs: pick your poison. JAMA Oncol. 2016;2(4):425–426. doi:10.1001/jamaoncol.2015.5813.
- Case A, Deaton A. How healthcare costs hurt American workers and benefit the wealthy. Time. 2020.
- Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. JCO. 2016;34(24):2925–2934. doi:10.1200/JCO.2016.68.2518.
- Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. JCO. 2015;33(23):2563–2577. doi:10.1200/JCO.2015.61.6706.
- Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996–1000. doi:10.1016/j.mayocp.2015.06.001.
- Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153–165. doi:10.3322/caac.21443.
- Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017;109:djw205.
- Knight TG, Deal AM, Dusetzina SB, Muss HB, Choi SK, Bensen JT, et al. Financial toxicity in adults with cancer: adverse outcomes and noncompliance. JOP. 2018;14(11):e665–e673. doi:10.1200/JOP.18.00120.
- Witte J, Mehlis K, Surmann B, Lingnau R, Damm O, Greiner W, et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol. 2019;30(7):1061–1070. doi:10.1093/annonc/mdz140.
- de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araújo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017;123(3):476–484. doi:10.1002/cncr.30369.
- Huang I-C, Bhakta N, Brinkman TM, Klosky JL, Krull KR, Srivastava D, et al. Determinants and consequences of financial hardship among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. J Natl Cancer Inst. 2019;111(2):189–200. doi:10.1093/jnci/djy120.
- Yabroff KR, Dowling EC, Guy GP, Banegas MP, Davidoff A, Han X, Jr, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34(3):259–267. doi:10.1200/JCO.2015.62.0468.
- Gilligan AM, Alberts DS, Roe DJ, Skrepnek GH. Death or debt? National estimates of financial toxicity in persons with newly-diagnosed cancer. Am J Med. 2018;131(10):1187–1199 e5. doi:10.1016/j.amjmed.2018.05.020.
- Prasad V, De Jesus K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381–390. doi:10.1038/nrclinonc.2017.31.
- Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. JCO. 2016;34(9):980–986. doi:10.1200/JCO.2015.64.6620.